{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T14:10:24Z","timestamp":1758723024454,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03926-w","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:08:50Z","timestamp":1745320130000},"page":"4003-4010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy for prostate cancer: incidence and impact on quality of life"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct04262609","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8522-5115","authenticated-orcid":false,"given":"Joan","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-9904","authenticated-orcid":false,"given":"Nicolas","family":"Feltes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-3391","authenticated-orcid":false,"given":"Maria","family":"Lizondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-6938","authenticated-orcid":false,"given":"Mamen","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9923","authenticated-orcid":false,"given":"Clara","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9254-2864","authenticated-orcid":false,"given":"Yolanda","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-134X","authenticated-orcid":false,"given":"Saturio","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-8820","authenticated-orcid":false,"given":"Manuel","family":"Galdeano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"17","key":"3926_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"issue":"2","key":"3926_CR2","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.ijrobp.2012.03.065","volume":"84","author":"D Alsadius","year":"2012","unstructured":"Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilder\u00e4ng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84(2):e181\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.065.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3926_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00384-012-1593-5","volume":"28","author":"R Krol","year":"2013","unstructured":"Krol R, Smeenk RJ, van Lin EN, Hopman WPM. Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. Int J Colorectal Dis. 2013;28(4):519\u201326. https:\/\/doi.org\/10.1007\/s00384-012-1593-5.","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"3926_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","volume":"73","author":"A Al-Mamgani","year":"2009","unstructured":"Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(3):685\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.04.063.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"3926_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1120\/jacmp.v17i6.6464","volume":"17","author":"W Ren","year":"2016","unstructured":"Ren W, Sun C, Lu N, Xu Y, Han F, Liu YP, et al. Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis. J Appl Clin Med Phys. 2016;17(6):254\u201362. https:\/\/doi.org\/10.1120\/jacmp.v17i6.6464.","journal-title":"J Appl Clin Med Phys"},{"issue":"38","key":"3926_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ctro.2022.11.001","volume":"8","author":"S Wang","year":"2022","unstructured":"Wang S, Tang W, Luo H, Jin F, Wang Y. The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022;8(38):81\u20139. https:\/\/doi.org\/10.1016\/j.ctro.2022.11.001.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"3926_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JU.0000000000000071","volume":"201","author":"SC Morgan","year":"2019","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019;201(3):528\u201334. https:\/\/doi.org\/10.1097\/JU.0000000000000071.","journal-title":"J Urol"},{"issue":"8","key":"3926_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol"},{"key":"3926_CR9","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978\u201394\u201392671\u201319\u20136. https:\/\/uroweb.org\/guidelines\/prostate-cancer. (Accessed 10 Jan 2024)."},{"key":"3926_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.06.961","author":"J Lozano","year":"2013","unstructured":"Lozano J, Pera O, Foro P, Lio J, Membrive I, Reig A, et al. A new dietary and laxative protocol reduces rectal distension and acute rectal toxicity in prostate cancer patients treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2013. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.06.961.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3926_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/gut.44.1.77","volume":"44","author":"CJ Vaizey","year":"1999","unstructured":"Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44(1):77\u201380. https:\/\/doi.org\/10.1136\/gut.44.1.77.","journal-title":"Gut"},{"issue":"5","key":"3926_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3926_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16(3):274\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(14)70482-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3926_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10350-006-0514-5","volume":"49","author":"M Minguez","year":"2006","unstructured":"Minguez M, Garrigues V, Soria MJ, Andreu M, Mearin F, Clave P. Adaptation to Spanish language and validation of the fecal incontinence quality of life scale. Dis Colon Rectum. 2006;49(4):490\u20139. https:\/\/doi.org\/10.1007\/s10350-006-0514-5.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"3926_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s10350-005-0049-1","volume":"48","author":"L Lundby","year":"2005","unstructured":"Lundby L, Krogh K, Jensen VJ, Gandrup P, Qvist N, Overgaard J, et al. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum. 2005;48(7):1343\u201352. https:\/\/doi.org\/10.1007\/s10350-005-0049-1.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"3926_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.radonc.2009.05.021","volume":"92","author":"NS Russell","year":"2009","unstructured":"Russell NS, Hoving S, Heeneman S, Hage JJ, Woerdeman LA, de Bree R, et al. Novel insights into pathological changes in muscular arteries of radiotherapy patients. Radiother Oncol. 2009;92(3):477\u201383. https:\/\/doi.org\/10.1016\/j.radonc.2009.05.021.","journal-title":"Radiother Oncol"},{"issue":"11","key":"3926_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S1470-2045(07)70341-8","volume":"8","author":"J Andreyev","year":"2007","unstructured":"Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8(11):1007\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(07)70341-8.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3926_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","volume":"106","author":"A Wilkins","year":"2020","unstructured":"Wilkins A, Naismith O, Brand D, Fernandez K, Hall E, Dearnaley D, et al. Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation. Int J Radiat Oncol Biol Phys. 2020;106(5):928\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3926_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666962","volume":"11","author":"P Sargos","year":"2021","unstructured":"Sargos P, Faye MD, Bacci M, Supiot S, Latorzeff I, Azria D, et al. Late gastrointestinal tolerance after prostate radiotherapy: is the anal canal the culprit? A Narrative Critical Rev Front Oncol. 2021;11: 666962. https:\/\/doi.org\/10.3389\/fonc.2021.666962.","journal-title":"A Narrative Critical Rev Front Oncol"},{"key":"3926_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fonc.2020.00469","volume":"10","author":"WD Heemsbergen","year":"2020","unstructured":"Heemsbergen WD, Incrocci L, Pos FJ, Heijmen BJM, Witte MG. Local dose effects for late gastrointestinal toxicity after hypofractionated and conventionally fractionated modern radiotherapy for prostate cancer in the HYPRO trial. Front Oncol. 2020;10:469. https:\/\/doi.org\/10.3389\/fonc.2020.00469.","journal-title":"Front Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03926-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03926-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03926-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:48:14Z","timestamp":1758721694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03926-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3926"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03926-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Research Ethics Committee (EC) of our Hospital (local EC number approval: 02\u201320-100\u2013077) in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was obtained from all eligible patients at inclusion time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}